Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Somerset Emsam "approvable

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Somerset receives "approvable" letter Jan. 30 for its transdermal selegiline patch, Emsam. The Mylan/Watson joint venture indicated that FDA is requesting additional pharmacology/toxicology studies as well as postmarketing pharmacokinetic and safety studies. Tyramine dietary restrictions in labeling are also requested. The sponsors resubmitted the Emsam NDA Aug. 1, 2003 for treatment of depression following a March 2002 "not approvable" letter (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 14)...

Somerset receives "approvable" letter Jan. 30 for its transdermal selegiline patch, Emsam . The Mylan/Watson joint venture indicated that FDA is requesting additional pharmacology/toxicology studies as well as postmarketing pharmacokinetic and safety studies. Tyramine dietary restrictions in labeling are also requested. The sponsors resubmitted the Emsam NDA Aug. 1, 2003 for treatment of depression following a March 2002 "not approvable" letter (1 (Also see "Somerset Emsam NDA Resubmission Adds Long-Term Indication, Higher Doses" - Pink Sheet, 1 Sep, 2003.), p. 14)....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS002471

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel